Early familial non-medullary thyroid cancer: differences with late-onset and sporadic forms
Authors' conclusion
These findings underscore the relevance of age at disease onset in shaping the clinical phenotypes of FNMTC. The distinct pathological features of early-onset vs late-onset FNMTC suggest different pathophysiological mechanisms, with the former likely driven by direct genetic/oncogenic alterations, and the latter influenced by autoimmune thyroiditis-related carcinogenesis, a hypothesis that warrants further investigation in larger prospective studies.
Study context
- Population
- Patients with non-medullary thyroid cancer, familial or sporadicage- and sex-matched
- Participants
- 31 vs 31
- Comparison
- Familial non-medullary thyroid cancer (FNMTC) vs sporadic NMTC (sporadic non-medullary thyroid cancer (sNMTC)); early-onset (≤35 years) vs late-onset (>35 years)
- FNMTCn = 31
- sNMTCn = 31reference
- Outcome
- Clinicopathological features
- Follow-up
- Diagnosis
Methodological detailsage- and sex-matched
- Age- and sex-matched
Main finding
As reported in the abstract
- FNMTC presented at a more advanced stage at diagnosis vs sNMTC, with a higher proportion of medium-high TNM stages
Observational data: associations, not effects.
Further findings
Early-onset (≤35 years) vs late-onset (>35 years) FNMTC
- Early-onset FNMTC: higher BRAF expression, more frequent lymph node metastases, higher proportion of medium-high TNM stages and intermediate-to-high ATA risk vs late-onset
- Late-onset FNMTC: higher prevalence of chronic lymphocytic thyroiditis (CLT) vs early-onset FNMTC and late-onset sNMTC
Early-onset FNMTC vs age-matched sNMTC
- Medium-high TNM stage, BRAF expression and lymph node metastases more frequent in early-onset FNMTC
Original publication
Early familial non-medullary thyroid cancer: differences with late-onset and sporadic forms. Eur J Endocrinol. Published 16 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →